Factor XI and pulmonary infections
- PMID: 29808936
- PMCID: PMC6278932
- DOI: 10.1111/hae.13503
Factor XI and pulmonary infections
Conflict of interest statement
DISCLOSURE
D Gailani is a paid consultant for several pharmaceutical companies (Bayer, Bristol-Myers-Squibb, Ionis, Janssen, Merck, Novartis) with interests in developing novel antithrombotic therapies. B. Mohammed and Q. Cheng, have no conflicts of interest to report. D.
References
-
- Weitz JI, Fredenburgh JC. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants. Arterioscler Thromb Vasc Biol 2018;38:304–310. - PubMed
-
- Salomon O, Preis M, A’asem Abu S, Kotler A, Stein N, Saliba W. Factor XI deficiency is not associated with pneumonia and pneumonia-related mortality Hameophilia (in press; ) - PubMed
-
- Naudin C, Burillo E, Blankenberg S, Butler L, Renné T. FXII contact activation. Semin Thromb Hemost 2017;43:814–826. - PubMed
-
- Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiology and physiologic activities. J Thromb Haemost 2016;14:28–39 - PubMed